Cover Image
市場調查報告書

唐氏症 : 開發中產品分析

Down Syndrome - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 251580
出版日期 內容資訊 英文 69 Pages
訂單完成後即時交付
價格
Back to Top
唐氏症 : 開發中產品分析 Down Syndrome - Pipeline Review, H2 2016
出版日期: 2016年07月13日 內容資訊: 英文 69 Pages
簡介

唐氏症是會造成一輩子認知障礙、發育遲緩等問題的遺傳性疾病。病症從輕微到嚴重各有不同。

本報告提供唐氏症治療藥的開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

唐氏症概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

調查中的治療藥:各大學/研究機關

開發中產品的概要

  • 臨床實驗階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

開發中的產品:各企業

調查中的產品:各大學/研究機關

開發治療藥的企業

  • AC Immune SA
  • Aelis Farma SAS
  • Cortice Biosciences, Inc.
  • Eisai
  • F. Hoffmann-La Roche Ltd.
  • NeuroNascent, Inc.
  • Transition Therapeutics Inc.

治療藥的評估

  • 單獨療法的情況
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

開發中止的產品

產品開發的里程碑

  • 最新消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8271IDB

Summary

Global Markets Direct's, 'Down Syndrome - Pipeline Review, H2 2016', provides an overview of the Down Syndrome pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Down Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Down Syndrome and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Down Syndrome
  • The report reviews pipeline therapeutics for Down Syndrome by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Down Syndrome therapeutics and enlists all their major and minor projects
  • The report assesses Down Syndrome therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Down Syndrome

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Down Syndrome
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Down Syndrome pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Down Syndrome Overview
  • Therapeutics Development
    • Pipeline Products for Down Syndrome - Overview
    • Pipeline Products for Down Syndrome - Comparative Analysis
  • Down Syndrome - Therapeutics under Development by Companies
  • Down Syndrome - Therapeutics under Investigation by Universities/Institutes
  • Down Syndrome - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Down Syndrome - Products under Development by Companies
  • Down Syndrome - Products under Investigation by Universities/Institutes
  • Down Syndrome - Companies Involved in Therapeutics Development
    • AC Immune SA
    • Aelis Farma SAS
    • Cortice Biosciences, Inc.
    • Eisai Co., Ltd.
    • F. Hoffmann-La Roche Ltd.
    • NeuroNascent, Inc.
    • Transition Therapeutics Inc.
  • Down Syndrome - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • ACI-24 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ALZ-801 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • APH-1104 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • basmisanil - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • D-217 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • donepezil hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Dosmir - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ELND-005 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • minocycline - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NNI-351 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NNI-362 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Pentylenetetrazol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Antagonize CB1R for Fragile X Syndrome and Down Syndrome - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to inhibit DYRK1A for CNS Diseases - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Down Syndrome - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit OLIG2 for Down Syndrome - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Stem Cell Therapy to Activate ZSCAN4 for Down Syndrome and Edwards Syndrome - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • xamoterol fumarate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Down Syndrome - Discontinued Products
  • Down Syndrome - Product Development Milestones
    • Featured News & Press Releases
      • Apr 05, 2016: AC Immune Announces Publication of Ground-breaking Scientific Publication on anti-Abeta Vaccine in Preclinical Model of Down Syndrome
      • Feb 05, 2015: Neuronascent Announces Expanded Patent Coverage in Russia for Its Down Syndrome Therapeutics
      • Nov 20, 2014: Transition Therapeutics Announces Results from ELND005 Clinical Study in Adults with Down Syndrome
      • Apr 07, 2014: Transition Therapeutics Announces Development Update
      • Sep 04, 2013: Transition Therapeutics Announces Dosing of the First Patient in Phase 2a Study of ELND005 in Down Syndrome
      • Sep 03, 2013: Elan Announces Dosing of First Patient in Phase 2a Trial of ELND005 (Scyllo-inositol) in Down Syndrome
      • Feb 27, 2013: Roche Provides Update On Its Clinical Candidate For Down Syndrome
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Down Syndrome, H2 2016
  • Number of Products under Development for Down Syndrome - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Down Syndrome - Pipeline by AC Immune SA, H2 2016
  • Down Syndrome - Pipeline by Aelis Farma SAS, H2 2016
  • Down Syndrome - Pipeline by Cortice Biosciences, Inc., H2 2016
  • Down Syndrome - Pipeline by Eisai Co., Ltd., H2 2016
  • Down Syndrome - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
  • Down Syndrome - Pipeline by NeuroNascent, Inc., H2 2016
  • Down Syndrome - Pipeline by Transition Therapeutics Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Down Syndrome - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Down Syndrome, H2 2016
  • Number of Products under Development for Down Syndrome - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top